A Phase 1 interventional study of BIA 2-093 and Moxifloxacin in Epilepsy, sponsored by Bial - Portela C S.A.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-11.
Sponsored by Bial - Portela C S.A. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing eslicarbazepine in Epilepsy — none open to participants now, none under way, none of them phase 3. eslicarbazepine · Epilepsy.
Among the 45 studies testing eslicarbazepine in Epilepsy, this one is the 14th largest by enrollment, is one of 7 that started in 2007, is one of 29 in phase 1, and was the 32nd registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →None of the 45 studies testing eslicarbazepine in Epilepsy is open now. The open studies under Epilepsy, anywhere →
eslicarbazepine: first FDA approval 2013 (APTIOM), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 32 across the 45 interventional studies. Of the 44 that completed or were terminated, 39 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 45 have an industry lead sponsor. The 2 most frequent:
Bial - Portela C S.A. is the lead sponsor of 136 studies on the registry; 1 is open to participants now.
44 studies in Epilepsy by Bial - Portela C S.A.: none open now, none under way, none of them phase 3. Of 44 finished, 37 (84%) have results posted.
Among the 44 studies in Epilepsy by Bial - Portela C S.A., this one is the 11th largest by enrollment of the 43 interventional ones that give a count, is one of 8 that started in 2007, is one of 31 in phase 1, and was the 30th registered.
Bial - Portela C S.A.’s Epilepsy studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 45 studies testing eslicarbazepine in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bial - Portela C S.A.’s 44 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind, placebo-controlled and open label active-controlled, 4 period crossover trial to evaluate the effect of eslicarbazepine acetate on cardiac repolarization in healthy adult men and women
The purpose of this randomized, double-blind, placebo-controlled and open label active-controlled, 4 period crossover study was to evaluate the effect of therapeutic and supra-therapeutic doses of eslicarbazepine acetate on the placebo corrected time-matched change from baseline using individually corrected QT (QTcI) interval durations in adult healthy volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
Drug: BIA 2-093 · Drug: Moxifloxacin · Drug: Placebo
A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
Drug: BIA 2-093 · Drug: Moxifloxacin · Drug: Placebo
A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
Drug: BIA 2-093 · Drug: Moxifloxacin · Drug: Placebo
A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
Drug: BIA 2-093 · Drug: Moxifloxacin · Drug: Placebo
Also known as: ESL, Eslicarbazepine acetate
Also known as: avalox
Also known as: PLC
QTcI - QT Interval Individually Corrected for Heart Rate - Day 5
Time frame: -30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose
QTcB - QT Interval Corrected for Heart Rate Using Bazett's Formula
Time frame: -30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose
QTcF - QT Interval Corrected Using Fridericia's Formula
Time frame: -30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose
| Milestone | Treatment Sequence ABCD | Treatment Sequence BDAC | Treatment Sequence CADB | Treatment Sequence DCBA |
|---|---|---|---|---|
| Started | 17 | 17 | 17 | 16 |
| Completed | 16 | 13 | 12 | 14 |
| Not completed | 1 | 4 | 5 | 2 |
| Withdrew: Adverse event | 1 | 3 | 5 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 |
| msec | BIA 2-093 1200 mg | BIA 2-093 2400 mg | Moxifloxacin 400 mg | Placebo |
|---|---|---|---|---|
| 0.5 hr | -8.05 ± 12.168 | -6.15 ± 10.891 | -2.77 ± 10.496 | -4.39 ± 9.985 |
| 1 hour | -9.34 ± 11.399 | -7.34 ± 11.822 | 3.80 ± 11.824 | -4.14 ± 9.515 |
| 1.5 hours | -8.70 ± 11.689 | -8.67 ± 10.525 | 5.30 ± 11.537 | -4.22 ± 10.432 |
| 2 hours | -9.48 ± 10.692 | -8.31 ± 10.738 | 6.87 ± 11.477 | -5.32 ± 10.189 |
| 3 hours | -8.04 ± 11.188 | -8.50 ± 13.142 | 8.49 ± 12.875 | -3.24 ± 11.178 |
| 4 hours | -7.72 ± 12.496 | -6.16 ± 13.563 | 10.13 ± 11.686 | -2.10 ± 9.899 |
| 5 hours | -3.54 ± 11.282 | -1.71 ± 12.567 | 7.07 ± 11.309 | -0.75 ± 10.090 |
| 6 hours | -4.59 ± 11.792 | -2.64 ± 12.856 | 5.83 ± 10.927 | -3.10 ± 10.537 |
| 8 hours | -2.63 ± 10.841 | -1.36 ± 11.281 | 5.80 ± 12.303 | -1.77 ± 10.586 |
| 12 hours | -0.01 ± 9.347 | 0.03 ± 13.311 | 5.85 ± 9.955 | -1.44 ± 9.150 |
| 16 hours | -3.72 ± 10.863 | -4.65 ± 12.930 | 5.21 ± 10.900 | -1.41 ± 12.835 |
| 23.5 hours | -3.36 ± 11.514 | -0.06 ± 12.605 | 2.39 ± 9.104 | -1.71 ± 9.513 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Sequence ABCD | — | 0/17 (0%) | 1/17 (5.9%) |
| Treatment Sequence BDAC | — | 0/17 (0%) | 3/17 (17.6%) |
| Treatment Sequence CADB | — | 0/17 (0%) | 5/17 (29.4%) |
| Treatment Sequence DCBA | — | 0/16 (0%) | 1/16 (6.3%) |
| Event | Treatment Sequence ABCD | Treatment Sequence BDAC | Treatment Sequence CADB | Treatment Sequence DCBA |
|---|---|---|---|---|
| dizzinessNervous system disorders | 1/17 | 3/17 | 5/17 | 1/16 |
| HEADACHENervous system disorders | 1/17 | 3/17 | 5/17 | 0/16 |
| Paraesthesia oralNervous system disorders | 0/17 | 3/17 | 3/17 | 1/16 |
| SomnolenceNervous system disorders | 0/17 | 2/17 | 3/17 | 1/16 |
| vomitingGastrointestinal disorders | 1/17 | 2/17 | 2/17 | 0/16 |
| NauseaGastrointestinal disorders | 0/17 | 1/17 | 2/17 | 0/16 |
| RashSkin and subcutaneous tissue disorders | 1/17 | 1/17 | 0/17 | 1/16 |
| PruritusSkin and subcutaneous tissue disorders | 0/17 | 0/17 | 1/17 | 1/16 |
| VISION BLURREDEye disorders | 0/17 | 0/17 | 1/17 | 1/16 |
| abdominal distensionGastrointestinal disorders | 0/17 | 0/17 | 1/17 | 0/16 |
| Age, Continuous(years) | Treatment Sequence ABCD | Treatment Sequence BDAC | Treatment Sequence CADB | Treatment Sequence DCBA | Total |
|---|---|---|---|---|---|
| Mean | 36.2 ± 7.55 | 33.6 ± 6.41 | 32.6 ± 7.88 | 35.8 ± 7.35 | 34.5 ± 7.31 |
| Sex: Female, Male(Participants) | Treatment Sequence ABCD | Treatment Sequence BDAC | Treatment Sequence CADB | Treatment Sequence DCBA | Total |
|---|---|---|---|---|---|
| Female | 7 | 9 | 10 | 9 | 35 |
| Male | 10 | 8 | 7 | 7 | 32 |
| Race (NIH/OMB)(Participants) | Treatment Sequence ABCD | Treatment Sequence BDAC | Treatment Sequence CADB | Treatment Sequence DCBA | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 0 | 4 | 1 | 9 |
| White | 13 | 16 | 13 | 15 | 57 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
The record gives a start of Mar 2007, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 7 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eslicarbazepine